METTL3 and colorectal carcinoma: In colorectal cancer (CRC), METTL3-mediated m6A modification enhances the binding of Sec62 with β-catenin, thereby enhancing Wnt signal transduction, promoting CRC stemness, and augmenting chemotherapy resistance [58].